<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">Connective tissue diseases</z:e> (CTDs) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of disorders that share certain clinical presentations and a disturbed immunoregulation, leading to autoantibody production </plain></SENT>
<SENT sid="1" pm="."><plain>Subclinical or overt renal manifestations are frequently observed and complicate the clinical course of CTDs </plain></SENT>
<SENT sid="2" pm="."><plain>Alterations of kidney function in <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome, systemic <z:hpo ids='HP_0100324'>scleroderma</z:hpo> (SSc), auto-immune <z:hpo ids='HP_0003198'>myopathies</z:hpo> (<z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> and <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e>), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (APSN) as well as <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) are frequently present and physicians should be aware of that.In SLE, renal prognosis significantly improved based on specific classification and treatment strategies adjusted to kidney biopsy findings </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:hpo ids='HP_0100324'>scleroderma</z:hpo> renal crisis (SRC), which is usually characterized by severe <z:hpo ids='HP_0000822'>hypertension</z:hpo>, progressive decline of renal function and <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e>, show a significant benefit of early angiotensin-converting-enzyme (ACE) inhibitor use in particular and strict blood pressure control in general </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of the underlying <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> or discontinuation of specific therapeutic agents improves kidney function in most patients with <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome, auto-immune <z:hpo ids='HP_0003198'>myopathies</z:hpo>, APSN and RA.In this review we focus on impairment of renal function in relation to underlying disease or adverse drug effects and implications on treatment decisions </plain></SENT>
</text></document>